AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Alzamend Neuro Inc
Video analysis: ALZN
All videosNo video analysis for this stock yet. Request one from our team.
News: ALZN
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026 in Washington, DC Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial ATLANTA, Aug. 20, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting resting-state functional magnetic resonance imaging ("fMRI") findings for AL001, Alzamend's novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience ("SfN"), to be held November 14–18, 2026 in Washington, DC. The abstract, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," will be presented as a poster in the Neuropsychiatric Disorders session (Session PSTR337) on Wednesday, November 18, 2026, from 8:00 a.m.
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001, Alzamend's novel organic lithium drug candidate, in healthy human subjects ATLANTA, Aug. 18, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting pharmacokinetic imaging data for AL001, Alzamend's novel organic lithium salt, has been accepted for oral presentation at the International Society for Magnetic Resonance in Medicine ("ISMRM") Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR, to be held from September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain. The abstract, titled "Pharmacokinetics Imaging of Lithium at 7T – Results from a Phase 1/2A Clinical Trial with a Novel Organic Lithium Salt" (Abstract #00047), was selected following a competitive review by the workshop's organizing committee and will be presented in the "Proffered Papers" oral session on Tuesday, September 29, 2026 at 1:35 PM local time.
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to support Alzamend's clinical programs and working capital needs ATLANTA, Aug. 4, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announced today that it has entered into a Securities Purchase Agreement (the "Agreement") with Ault Lending, LLC ("Ault Lending"), pursuant to which Ault Lending has agreed to purchase up to $25,000,000 of the Company's newly designated Series D Convertible Preferred Stock (the "Preferred Shares"), and closed on the initial tranche in the amount of $7.5 million. Under the terms of the Agreement, Ault Lending agreed to purchase up to 25,000 Preferred Shares at a purchase price of $1,000 per share, for an aggregate purchase price of $25,000,000, with each Preferred Share having a stated value of $1,050.
